Leerink Partners maintains Medline at Outperform, raises price target to $46 from $43
Leerink Partners kept Medline at Outperform, raising its price target to $46 from $43, suggesting 14% upside from the Nov 4 close. Recent analyst targets range from $43 to $55.
How this was made

The 30-second read
Why it matters
The target increase reflects a modest bullish view but does not constitute a material catalyst for the broader market.
Market read
A small analyst rating change with limited trading relevance.
What to watch
Medline remains privately held, limiting liquidity and broader market impact.
Background
Analyst Leerink Partners upgraded Medline's price target from $43 to $46, implying a 14% upside from the recent close.
Market effects
Minimal impact on medical supplies sector as the change is a modest analyst target adjustment.
No regional effect.
Limited to investors tracking Medline analyst coverage.
Counterpoint
The target raise may be overly optimistic given limited growth catalysts.
Key entities
- companyMedline
Medical supplies manufacturer, privately held.
- analystLeerink Partners
Equity research firm providing the rating upgrade.